Howard Gurney

Personal profile

Biography

Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.

Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.

Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Prostatic Neoplasms Medicine & Life Sciences

Renal Cell Carcinoma Medicine & Life Sciences

Therapeutics Medicine & Life Sciences

Drug Therapy Medicine & Life Sciences

Castration Medicine & Life Sciences

docetaxel Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2024

1 Not started
2 Finished
13 Active

A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.

16/05/19 → 15/05/24

Project: Other

MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.

Gurney, H. & Cunningham, J.

1/04/19 → 30/04/20

Project: Other

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Gurney, H., Chapman, N. & Butala, R.

28/02/19 → 27/02/24

Project: Other

Misc_Novotech: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Gurney, H. & Cunningham, J.

17/07/18 → 5/06/23

Project: Other

MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors

Gurney, H., Butala, R. & Cunningham, J.

16/07/18 → 15/07/23

Project: Other

Research Outputs 1987 2019

7217 Citations
36 h-Index
95 Article
18 Review article
17 Meeting abstract
8 Letter
7 More

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 othersBedke, J., Choueiri, T. K., Parnis, F., Khaznadar, T., Thobhani, A., Li, S., Piault-Louis, E., Frantz, G., Huseni, M., Schiff, C., Green, M. C. & Motzer, R. J., 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Renal Cell Carcinoma

Randomized Controlled Trials

Disease-Free Survival

Ligands

Research Personnel

Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., Lee, J. L., Vasiliev, A., Miller, W. H., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Bedke, J., Alekseev, B., Wang, J. & 8 othersMariani, M., Robbins, P. B., Chudnovsky, A., Fowst, C., Hariharan, S., Huang, B., Di Pietro, A. & Choueiri, T. K., 21 Mar 2019, In : New England Journal of Medicine. 380, 12, p. 1103-1115 13 p.

Research output: Contribution to journal › Article › Research › peer-review

Renal Cell Carcinoma

Disease-Free Survival

sunitinib

avelumab

axitinib